天然产品作为PCSK9调节剂的作用:一篇综述
Danial Khayatan1,2, Kimia Zare3, Maryam Khanahmadi1,2
1Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Phytotherapy research : PTR
|June 20, 2024
概括
天然产品和植物化学物质可以抑制蛋白转化酶亚素/素9型 (PCSK9),有助于降低LDL胆固醇并预防心血管疾病. 本综述探讨了它们的作用机制.
科学领域:
- 心血管研究研究心血管研究
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心血管疾病 (CVD) 是一个主要的健康问题,通常与异常的脂质水平有关.
- 蛋白转化酶亚素/素9型 (PCSK9) 通过调节LDL受体 (LDLR) 降解,在低密度脂蛋白胆固醇 (LDL-C) 代谢中发挥关键作用.
- PCSK9 抑制剂在治疗脂质不良症和降低心血管风险方面已证明有效.
研究的目的:
- 审查天然产品和植物化学品作为PCSK9抑制剂的作用.
- 评估这些天然化合物在预防心血管疾病方面的潜力.
- 阐明天然PCSK9抑制剂的作用机制.
主要方法:
- 在体内和体外研究的文献综述.
- 对植物化学物质及其对脂质代谢的影响的研究分析.
- 对研究与PCSK9.9相关的天然产品机制的评估.
主要成果:
- 自然产品和植物化学物质可以调节PCSK9的活性.
- 这些化合物显示出控制脂质水平和预防心血管疾病的潜力.
- 不同的自然剂表现出不同的调节PCSK9.9的机制.
结论:
- 植物化学品和天然产品为开发新型PCSK9抑制剂提供了一个有希望的途径.
- 用天然化合物向PCSK9可能为心血管疾病预防提供战略.
- 需要进一步的研究,以充分阐明这些天然剂的机制.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
646
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
646
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157


